Article
How will PARP inhibitors change advanced PCa treatment?
Urology Times asked Maha H. Hussain, MD: How will the advent of PARP inhibitors change the management of advanced prostate cancer?
Urology Times asked Maha H. Hussain, MD: How will the advent of PARP inhibitors change the management of advanced prostate cancer?
For more on PARP inhibitors, see: PARP inhibitor significantly extends rPFS vs. hormonal therapy
More videos:
Focal therapy vs. surveillance for low-risk PCa
Medicare final rule: Changes affect cysto, prostate Bx reimbursement
Related Videos
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Rana McKay, MD, on the role of radium-223 in the modern era
Dr Louise Kostos discusses PSA kinetics in mHSPC
The importance of PSADT in high-risk, biochemically recurrent prostate cancer
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
Related Content
